Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Brighter AB (publ)
  6. News
  7. Summary
    BRIG   SE0004019545

BRIGHTER AB (PUBL)

(BRIG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Compatibility with New Insulins Opens Up New Market Opportunities for Brighter's Actiste

06/07/2021 | 09:46am EDT

Brighter AB (publ) announced today that its solution for diabetes management - the Actiste®, has been evaluated and proved to be compatible with insulin cartridges from BIOTON S.A. (SciGen Pte. Ltd.  - the exclusive distributor of BIOTON products, excluding Poland) with GENSULIN®GENSULIN® N (Scilin®N), GENSULIN® R (Scilin®R), and GENSULIN® M30(Scilin®M30). Currently, Actiste® is intended for use only with insulin cartridges from Sanofi. This has been a limiting factor to Brighter's potential market reach, because Sanofi cartridges are not available in all markets.   

"This is a great strategic move and a huge milestone for Brighter. It will open up additional markets with new revenue opportunities worldwide where Bioton / Scigen insulin is available. After finalizing the internal development work, we expect that Actiste® will be marketable for use with the additional insulin and ready for end users already in the second half of the year, says Christer Trägårdh, acting CEO of Brighter.

BIOTON S.A. is an innovative Polish biotechnology company, which provides patients with safe and complete solutions for diabetes care. Bioton is an unquestionable leader on the Polish market, and in the world's top eight commercial manufacturers of recombinant human insulin.

SciGen Pte. Ltd. is a high growth biopharmaceutical company that focuses on recombinant human health care biotechnology derived products. SciGen's focus is in the areas of endocrinology and oncology. The company's portfolio consists of biosimilar products such as rhuman growth hormone, rhuman insulin and rhuman GCSF. All of SciGen's products have undergone substantial clinical development

For more information, please contact:

Investor Relations
ir@brighter.se

Certified Adviser

Brighter's Certified Adviser is Eminova Fondkommission AB, +46 [0)8 - 684 211 10, adviser@eminova.se, www.eminova.se.

About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers - aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.

This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 15:45 CET on June 7, 2021

https://news.cision.com/brighter-ab--publ-/r/compatibility-with-new-insulins-opens-up-new-market-opportunities-for-brighter-s-actiste-,c3362425

https://mb.cision.com/Main/13292/3362425/1428655.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
BIOTON S.A. -1.24% 4.76 End-of-day quote.9.93%
BRIGHTER AB (PUBL) -2.65% 0.92 Delayed Quote.-67.41%
SANOFI 0.16% 82.86 Real-time Quote.5.12%
All news about BRIGHTER AB (PUBL)
10:46aBRIGHTER : subsidiary Camanio wins allocation decision with Borgholm Municipality for stat..
AQ
03:22aBRIGHTER : 23 Sep, 2021 Brighter Publishe s Q&A following Capital Markets Day held on 9 Se..
PU
03:09aBRIGHTER : Publishe s Q&A following Capital Markets Day held on 9 September 2021
AQ
09/21BRIGHTER : Starts Collaboration With Padjadjaran University, Indonesia; Shares Down 17%
MT
09/21BRIGHTER : 21 Sep, 2021 Brighter signs a collaboration agreement for Actiste Mini with Pad..
PU
09/21BRIGHTER : signs a collaboration agreement for Actiste Mini with Padjadjaran University in..
AQ
09/21Brighter Signs Collaboration Agreement for Actiste Mini with Padjadjaran University in ..
CI
09/20BRIGHTER : 20 Sep, 2021 Brighter's Actiste« receives final outstanding approval in Qatar
PU
09/20BRIGHTER : Actiste« receives final outstanding approval in Qatar
AQ
09/20Brighter's Actiste Receives Final Outstanding Approval in Qatar
CI
More news
Financials
Sales 2021 41,0 M 4,76 M 4,76 M
Net income 2021 -171 M -19,8 M -19,8 M
Net Debt 2021 135 M 15,7 M 15,7 M
P/E ratio 2021 -1,77x
Yield 2021 -
Capitalization 359 M 41,6 M 41,7 M
EV / Sales 2021 12,0x
EV / Sales 2022 2,52x
Nbr of Employees 74
Free-Float 93,6%
Chart BRIGHTER AB (PUBL)
Duration : Period :
Brighter AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRIGHTER AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,92 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Erik Lissner Chief Executive Officer
Christer Trńgňrdh Chairman
┼sa Hallin Dahlberg Head-Research & Development
Jan Ingvar Georg Stňlemark Director
Emanuel LipschŘtz Director
Sector and Competitors
1st jan.Capi. (M$)
BRIGHTER AB (PUBL)-67.41%43
VEEVA SYSTEMS INC.9.26%45 634
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED-47.77%19 980
OMNICELL, INC.31.04%6 837
PRO MEDICUS LIMITED72.51%4 390
SECTRA AB (PUBL)31.02%4 278